Thyrocare Technologies Limited — Updates, 23-10-2024: Press Release

Thyrocare Technologies Limited reported a 20% year-over-year increase in consolidated revenue, reaching INR 177.4 crore for Q2FY25, driven by growth in both Pathology and Radiology segments. Standalone EBITDA rose by 33%, while PAT increased by 45%. The company opened two new labs and completed acquisitions to enhance its network. Gross margins remained strong at 71%, with a normalized EBITDA margin of 29%.